Anti mouse pd l1 10f 9g2

B16F10 and TC-1 mouse tumor cell lines were purchased from ATCC and passaged in DMEM medium containing 10% FBS, 1% penicillin–streptomycin (all from Gibco) in TC-treated Cell Culture Dishes (SPL). At 70%–80% confluency, cancer cells were washed once with PBS (GenDepot) and detached using TrypLE Express (Gibco). B16F10 cells in PBS were either intravenously (1.0–4.0×10⁵ cells), intrasplenically (5.0×10⁵ cells), or subcutaneously (3.0×10⁵ cells) injected into mice. TC-1 cells were intravenously injected into mice (5.0×10⁵ cells). In indicated experiments, mice were intraperitoneally treated with either rat IgG2b (LTF-2; BioXCell) or anti-CD4 depleting antibody (GK1.5; BioXCell) at 100–200 µg/head doses every 4 to 5 days. In addition, anti-mouse CD127 (A7R34; BioXCell), anti-mouse Ly6G (1A8; BioXCell), or anti-mouse PD-L1 (10F.9G2; BioXCell) was intraperitoneally treated at 100 µg/head every 4 days. For RORγt inhibition, ursolic acid (U6753; Sigma Aldrich) dissolved in DMSO was intraperitoneally treated at 150 mg/kg every other day. For Tc17 adoptive transfer experiment, Tc17 cells generated in vitro from naïve CD8⁺ T cells isolated from CD45.1⁺ Pmel mice (3.0×10⁶ cells) were adoptively transferred into C57BL/6 mice 1 day before B16F10 tumor intravenous injection. Mice were sacrificed on days 14–19 after tumor cell injection.